JP2015504047A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015504047A5 JP2015504047A5 JP2014548337A JP2014548337A JP2015504047A5 JP 2015504047 A5 JP2015504047 A5 JP 2015504047A5 JP 2014548337 A JP2014548337 A JP 2014548337A JP 2014548337 A JP2014548337 A JP 2014548337A JP 2015504047 A5 JP2015504047 A5 JP 2015504047A5
- Authority
- JP
- Japan
- Prior art keywords
- dose
- cell
- cells
- depleted
- immature hematopoietic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000001744 T-lymphocyte Anatomy 0.000 claims 25
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 25
- 210000004027 cell Anatomy 0.000 claims 9
- 210000001519 tissue Anatomy 0.000 claims 6
- 230000037396 body weight Effects 0.000 claims 5
- 238000002054 transplantation Methods 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 230000003211 malignant effect Effects 0.000 claims 4
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 229940127089 cytotoxic agent Drugs 0.000 claims 3
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims 2
- 229960000390 fludarabine Drugs 0.000 claims 2
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 230000001400 myeloablative effect Effects 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- 102000006395 Globulins Human genes 0.000 claims 1
- 108010044091 Globulins Proteins 0.000 claims 1
- 208000024556 Mendelian disease Diseases 0.000 claims 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 claims 1
- 230000001494 anti-thymocyte effect Effects 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 229960002092 busulfan Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 230000003394 haemopoietic effect Effects 0.000 claims 1
- 210000002216 heart Anatomy 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 208000018706 hematopoietic system disease Diseases 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 210000001165 lymph node Anatomy 0.000 claims 1
- 229960001924 melphalan Drugs 0.000 claims 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 210000000952 spleen Anatomy 0.000 claims 1
- 229960001196 thiotepa Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161578917P | 2011-12-22 | 2011-12-22 | |
| US61/578,917 | 2011-12-22 | ||
| PCT/IL2012/050542 WO2013093920A2 (en) | 2011-12-22 | 2012-12-20 | A combination therapy for a stable and long term engraftment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015504047A JP2015504047A (ja) | 2015-02-05 |
| JP2015504047A5 true JP2015504047A5 (enExample) | 2016-01-21 |
Family
ID=48669650
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014548337A Pending JP2015504047A (ja) | 2011-12-22 | 2012-12-20 | 安定かつ長期の生着のための併用療法 |
| JP2014548336A Active JP6313219B2 (ja) | 2011-12-22 | 2012-12-20 | Ｔ細胞／ｂ細胞枯渇化のための特異的プロトコルを使用する安定かつ長期の生着のための併用療法 |
| JP2018007779A Pending JP2018080201A (ja) | 2011-12-22 | 2018-01-22 | Ｔ細胞／ｂ細胞枯渇化のための特異的プロトコルを使用する安定かつ長期の生着のための併用療法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014548336A Active JP6313219B2 (ja) | 2011-12-22 | 2012-12-20 | Ｔ細胞／ｂ細胞枯渇化のための特異的プロトコルを使用する安定かつ長期の生着のための併用療法 |
| JP2018007779A Pending JP2018080201A (ja) | 2011-12-22 | 2018-01-22 | Ｔ細胞／ｂ細胞枯渇化のための特異的プロトコルを使用する安定かつ長期の生着のための併用療法 |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US10434121B2 (enExample) |
| EP (2) | EP2797421B1 (enExample) |
| JP (3) | JP2015504047A (enExample) |
| KR (2) | KR102109643B1 (enExample) |
| CN (2) | CN104093314A (enExample) |
| AU (3) | AU2012355990B2 (enExample) |
| BR (2) | BR112014015960A8 (enExample) |
| CA (2) | CA2859952C (enExample) |
| DK (2) | DK2797421T3 (enExample) |
| ES (2) | ES2811529T3 (enExample) |
| IN (2) | IN2014MN01468A (enExample) |
| MX (2) | MX2014007648A (enExample) |
| RU (2) | RU2648354C2 (enExample) |
| SG (3) | SG11201403459XA (enExample) |
| WO (2) | WO2013093919A2 (enExample) |
| ZA (2) | ZA201405071B (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013035099A1 (en) | 2011-09-08 | 2013-03-14 | Yeda Research And Development Co. Ltd. | Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment |
| PT2788009T (pt) | 2011-12-08 | 2016-08-31 | Yeda Res & Dev | Células pulmonares fetais de mamíferos e uso terapêutico das mesmas |
| JP2015504047A (ja) | 2011-12-22 | 2015-02-05 | イェダ リサーチ アンド デベロップメント カンパニー リミテッド | 安定かつ長期の生着のための併用療法 |
| CA3206342A1 (en) | 2013-05-09 | 2014-11-13 | Advanced Neuroregenerative Therapies, Llc | G-csf for use in treating or preventing a disease with age and disease immune dysfunction and cellular senescence |
| EP4026563B1 (en) | 2015-06-18 | 2025-10-29 | Yeda Research and Development Co. Ltd | Conditioning protocols and use of same for tissue regeneration |
| EP3322424B1 (en) | 2015-07-16 | 2023-10-11 | Yeda Research and Development Co., Ltd. | Use of anti third party central memory t cells |
| CN108025023A (zh) * | 2015-08-25 | 2018-05-11 | Uab研究基金会 | 用于干细胞移植的方法 |
| RU2747728C2 (ru) * | 2015-12-04 | 2021-05-13 | Фред Хатчинсон Кэнсер Рисерч Сентер | Применение размноженных популяций гематопоэтических стволовых клеток/клеток-предшественников |
| EP3463402B1 (en) * | 2016-05-22 | 2021-06-23 | Yeda Research and Development Co. Ltd. | Methods of using pulmonary cells for transplantation and induction of tolerance |
| EP4011381A1 (en) * | 2016-06-03 | 2022-06-15 | Memorial Sloan-Kettering Cancer Center | Adoptive cell therapies as early treatment options |
| ES3064681T3 (en) | 2017-01-18 | 2026-04-28 | Yeda Res And Development Co Ltd | Genetically modified veto cells and use of same in immunotherapy |
| US10751368B2 (en) | 2017-01-18 | 2020-08-25 | Yeda Research And Development Co. Ltd. | Methods of transplantation and disease treatment |
| EP3571230A4 (en) | 2017-01-20 | 2020-12-16 | Magenta Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR DELETION OF CD137 + CELLS |
| EP4417210A1 (en) | 2017-03-15 | 2024-08-21 | Orca Biosystems, Inc. | Compositions and methods for hematopoietic stem cell transplants |
| IL274632B2 (en) * | 2017-11-15 | 2024-12-01 | Weird Science Llc | Methods and compositions for non-myeloablative bone marrow reconstitution |
| CN119857155A (zh) | 2017-11-29 | 2025-04-22 | 海德堡医药研究有限责任公司 | 用于耗尽cd5+细胞的组合物和方法 |
| EP3723785A1 (en) * | 2017-12-17 | 2020-10-21 | Yeda Research and Development Co. Ltd | Cop9 signalosome (csn) complex modulators and uses thereof |
| EP3749334B1 (en) | 2018-02-08 | 2024-12-11 | The Board of Trustees of the Leland Stanford Junior University | Allogenic hematopoietic stem cell transplantation |
| WO2019178106A1 (en) * | 2018-03-12 | 2019-09-19 | Medeor Therapeutics, Inc. | Methods for treating non-cancerous disorders using hematopoietic cells |
| US10842821B2 (en) * | 2018-04-05 | 2020-11-24 | Medeor Therapeutics, Inc. | Cellular compositions derived from prior organ donors and methods of manufacture and use thereof |
| US10881692B2 (en) * | 2018-04-05 | 2021-01-05 | Medeor Therapeutics, Inc. | Compositions for establishing mixed chimerism and methods of manufacture thereof |
| CA3107383A1 (en) * | 2018-07-23 | 2020-01-30 | Magenta Therapeutics, Inc. | Use of anti-cd5 antibody drug conjugate (adc) in allogeneic cell therapy |
| US11435350B2 (en) | 2018-09-18 | 2022-09-06 | Medeor Therapeutics, Inc. | Methods of analysis of blood from deceased donors |
| US11813376B2 (en) | 2018-09-18 | 2023-11-14 | Medeor Therapeutics, Inc. | Cellular compositions derived from deceased donors to promote graft tolerance and manufacture and uses thereof |
| CA3112320A1 (en) * | 2018-09-18 | 2020-03-26 | Medeor Therapeutics, Inc. | Cellular compositions derived from deceased donors to promote graft tolerance and manufacture and uses thereof |
| CA3114292A1 (en) * | 2018-09-27 | 2020-04-02 | Phosphogam, Inc. | Methods and compositions for the expansion and use of allogeneic gamma/delta-t cells |
| US20210380946A1 (en) * | 2018-11-01 | 2021-12-09 | Children's Hospital Medical Center | Reduced intensity conditioning with melphalan |
| CN109781987B (zh) * | 2019-01-09 | 2022-04-26 | 暨南大学 | 终末效应t细胞亚群在制备辅助评估再生障碍性贫血病情程度试剂盒中的应用 |
| EP3953383A4 (en) * | 2019-04-08 | 2023-01-18 | Russell Biotech, Inc. | Improved manufacturing procedures for cell based therapies |
| NZ781538A (en) | 2019-04-24 | 2025-12-19 | Heidelberg Pharma Res Gmbh | Amatoxin antibody-drug conjugates and uses thereof |
| RU2723164C1 (ru) * | 2019-10-07 | 2020-06-09 | Федеральное государственное бюджетное учреждение науки "Кировский научно-исследовательский институт гематологии и переливания крови Федерального медико-биологического агентства" | Способ расчета дозы клеток-предшественниц гемопоэза в лейкоцитаферезном продукте путем учета изменения целостности клеточных мембран при хранении |
| JP2023500277A (ja) * | 2019-11-05 | 2023-01-05 | イェダ リサーチ アンド デベロップメント カンパニー リミテッド | Ｔ細胞媒介性自己免疫疾患の治療におけるベト細胞の使用 |
| WO2021243190A1 (en) * | 2020-05-28 | 2021-12-02 | Biomagnetic Solutions Llc | Compositions and methods for negative selection of naive t and b cells with a single antibody |
| WO2022133282A1 (en) * | 2020-12-18 | 2022-06-23 | Ossium Health, Inc. | Methods of cell therapies |
| CN112669992B (zh) * | 2020-12-30 | 2024-06-11 | 中国人民解放军总医院 | 单倍体造血干细胞移植atg个体化用药量的计算方法 |
| RU2764742C1 (ru) * | 2021-04-09 | 2022-01-20 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр трансплантологии и искусственных органов имени академика В.И. Шумакова" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ ТИО им. академика В.И. Шумакова" Минздрава России) | Способ подбора режима иммуносупрессии детям раннего возраста в отдаленном периоде после трансплантации печени |
| US20250114360A1 (en) * | 2022-02-03 | 2025-04-10 | The Regents Of The University Of California | Novel regimen for augmenting and extending transplant tolerance |
| WO2024073751A1 (en) | 2022-09-29 | 2024-04-04 | Vor Biopharma Inc. | Methods and compositions for gene modification and enrichment |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| NL154599B (nl) | 1970-12-28 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking. |
| US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
| US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
| US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
| NL171930C (nl) | 1972-05-11 | 1983-06-01 | Akzo Nv | Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen. |
| US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
| US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
| US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
| US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
| US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
| US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
| US5635156A (en) | 1993-09-13 | 1997-06-03 | University Of Pittsburgh | Non-lethal methods for conditioning a recipient for bone marrow transplantation |
| US20010009663A1 (en) | 1993-09-13 | 2001-07-26 | Suzanne T. Ildstad | Non-lethal methods for conditioning a recipient for bone marrow transplantation |
| US6217867B1 (en) | 1993-09-13 | 2001-04-17 | University Of Pittsburgh | Non-lethal methods for conditioning a recipient for bone marrow transplantation |
| US5514364A (en) | 1993-09-13 | 1996-05-07 | University Of Pittsburgh | Non-lethal methods for conditioning a recipient for bone marrow transplantation |
| IL107483A0 (en) * | 1993-11-03 | 1994-02-27 | Yeda Res & Dev | Bone marrow transplantation |
| IL112969A (en) * | 1994-03-17 | 2001-05-20 | Baxter Int | Pharmaceutical compositions for the treatment of cancer comprising allogenic lymphocytes or their combination with a t-cell activator |
| EP1011694A4 (en) * | 1996-11-15 | 2000-11-15 | Baxter Int | TREATMENT FOR ALLOGENIC STEM CELL TRANSPLANTATION |
| US6039684A (en) | 1997-12-11 | 2000-03-21 | Allegheny University Of The Health Sciences | Non-lethal conditioning methods for the treatment of acquired immunodeficiency syndrome |
| AU2003204277B2 (en) | 1997-11-14 | 2006-03-16 | The General Hospital Corporation | Treatment of hematologic disorders |
| AU1585799A (en) | 1997-11-14 | 1999-06-07 | General Hospital Corporation, The | Treatment of hematologic disorders |
| AU765085B2 (en) * | 1998-05-11 | 2003-09-11 | Miltenyi Biotec Gmbh | Method of direct selection of antigen-specific T cells |
| CA2279474C (en) | 1998-07-31 | 2011-01-04 | Stemcell Technologies Inc. | Novel antibody composition for debulking blood and bone marrow samples from cml patients |
| WO2002040640A2 (en) | 2000-11-14 | 2002-05-23 | The University Of Louisville Research Foundation, Inc. | Methods of using cd8+/tcr- facilitating cells (fc) for the engraftment of purified hematopoietic stem cells (hsc) |
| AU2002220165A1 (en) | 2000-11-14 | 2002-05-27 | The University Of Louisville Research Foundation, Inc. | Non-lethal methods for conditioning a recipient for bone marrow transplantation |
| AU2002239424A1 (en) | 2000-11-14 | 2002-05-27 | The University Of Louisville Research Foundation, Inc. | Methods for enhancing engraftment of purified hematopoietic stem cells in allogeneic recipients |
| WO2002089746A2 (en) | 2001-05-09 | 2002-11-14 | The University Of Louisville Research Foundation, Inc. | Hematopoietic stem cell chimerism to treat autoimmune disease |
| WO2003012060A2 (en) | 2001-08-01 | 2003-02-13 | Jewish Hospital Healthcare Services, Inc. | Cellular compositions which facilitate engraftment of hematopoietic stem cells while minimizing the risk of gvhd |
| WO2005001040A2 (en) | 2003-05-28 | 2005-01-06 | Univ. Of Louisville Research Foundation, Inc. | Non-lethal conditioning methods for conditioning a recipient for bone marrow transplantation |
| WO2005023982A2 (en) | 2003-05-28 | 2005-03-17 | Univ. Of Louisville Research Foundation, Inc. | Methods for enhancing engraftment of purified hematopoietic stem cells in allogenic recipients |
| WO2009094456A2 (en) * | 2008-01-22 | 2009-07-30 | Johns Hopkins University | Use of high-dose, post-transplantation oxazaphosphorine drugs for reduction of transplant rejection |
| US8632768B2 (en) | 2008-05-30 | 2014-01-21 | University Of Louisville Research Foundation, Inc. | Human facilitating cells |
| DE102009040716B4 (de) * | 2009-09-10 | 2011-07-14 | Miltenyi Biotec GmbH, 51429 | Verwendung von CD154 zur Identifizierung und Abtrennung von nicht-regulatorischen T-Zellen aus einem Gemisch mit regulatorischen T-Zellen |
| JP2015504047A (ja) | 2011-12-22 | 2015-02-05 | イェダ リサーチ アンド デベロップメント カンパニー リミテッド | 安定かつ長期の生着のための併用療法 |
| US20210045900A1 (en) | 2019-08-13 | 2021-02-18 | Stryker Corporation | Stent braid pattern with enhanced radiopacity |
-
2012
- 2012-12-20 JP JP2014548337A patent/JP2015504047A/ja active Pending
- 2012-12-20 DK DK12861023.5T patent/DK2797421T3/da active
- 2012-12-20 CN CN201280068917.4A patent/CN104093314A/zh active Pending
- 2012-12-20 ES ES12861023T patent/ES2811529T3/es active Active
- 2012-12-20 ES ES12859036T patent/ES2864323T3/es active Active
- 2012-12-20 KR KR1020147020449A patent/KR102109643B1/ko active Active
- 2012-12-20 SG SG11201403459XA patent/SG11201403459XA/en unknown
- 2012-12-20 CN CN201280068202.9A patent/CN104470542A/zh active Pending
- 2012-12-20 EP EP12861023.5A patent/EP2797421B1/en active Active
- 2012-12-20 RU RU2014129632A patent/RU2648354C2/ru active
- 2012-12-20 MX MX2014007648A patent/MX2014007648A/es active IP Right Grant
- 2012-12-20 AU AU2012355990A patent/AU2012355990B2/en not_active Ceased
- 2012-12-20 MX MX2014007647A patent/MX370404B/es active IP Right Grant
- 2012-12-20 KR KR1020147020448A patent/KR20140105848A/ko not_active Withdrawn
- 2012-12-20 BR BR112014015960A patent/BR112014015960A8/pt not_active IP Right Cessation
- 2012-12-20 SG SG10201801905WA patent/SG10201801905WA/en unknown
- 2012-12-20 IN IN1468MUN2014 patent/IN2014MN01468A/en unknown
- 2012-12-20 RU RU2014128479A patent/RU2657758C2/ru active
- 2012-12-20 BR BR112014015959A patent/BR112014015959A8/pt active Search and Examination
- 2012-12-20 CA CA2859952A patent/CA2859952C/en active Active
- 2012-12-20 US US14/367,923 patent/US10434121B2/en active Active
- 2012-12-20 SG SG11201403456UA patent/SG11201403456UA/en unknown
- 2012-12-20 EP EP12859036.1A patent/EP2793914B1/en active Active
- 2012-12-20 DK DK12859036.1T patent/DK2793914T3/da active
- 2012-12-20 AU AU2012355989A patent/AU2012355989B2/en not_active Ceased
- 2012-12-20 CA CA2859953A patent/CA2859953A1/en not_active Abandoned
- 2012-12-20 US US14/367,917 patent/US10369172B2/en active Active
- 2012-12-20 WO PCT/IL2012/050541 patent/WO2013093919A2/en not_active Ceased
- 2012-12-20 IN IN1467MUN2014 patent/IN2014MN01467A/en unknown
- 2012-12-20 WO PCT/IL2012/050542 patent/WO2013093920A2/en not_active Ceased
- 2012-12-20 JP JP2014548336A patent/JP6313219B2/ja active Active
-
2014
- 2014-07-11 ZA ZA2014/05071A patent/ZA201405071B/en unknown
- 2014-07-18 ZA ZA2014/05298A patent/ZA201405298B/en unknown
-
2016
- 2016-11-18 AU AU2016259415A patent/AU2016259415B2/en not_active Ceased
-
2018
- 2018-01-22 JP JP2018007779A patent/JP2018080201A/ja active Pending
-
2019
- 2019-07-11 US US16/508,325 patent/US11497776B2/en active Active
- 2019-08-13 US US16/538,954 patent/US11504399B2/en active Active
-
2022
- 2022-10-02 US US17/958,401 patent/US20230039904A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015504047A5 (enExample) | ||
| RU2014128479A (ru) | Комбинированная терапия для стабильного и долговременного приживления трансплантата | |
| Vaikunthanathan et al. | Regulatory T cells: tolerance induction in solid organ transplantation | |
| Aversa et al. | The evolution of T cell depleted haploidentical transplantation | |
| JP2015502401A5 (enExample) | ||
| JP2016516672A5 (enExample) | ||
| JP2015524415A5 (enExample) | ||
| Czechowicz et al. | Purified hematopoietic stem cell transplantation—the next generation of blood and immune replacement | |
| ES2980858T3 (es) | Método mejorado para la expansión ex vivo de HSPC CD34+ en células NK usando un antagonista del receptor de aril hidrocarburos | |
| Petrus et al. | An immunoablative regimen of fludarabine and cyclophosphamide prevents fully MHC-mismatched murine marrow graft rejection independent of GVHD | |
| Qin et al. | Evaluation of ex vivo produced endothelial progenitor cells for autologous transplantation in primates | |
| JP2022515144A (ja) | オフザシェルフのダブルネガティブｔ細胞の産生および治療的使用 | |
| Voltarelli et al. | Stem cell transplantation for type 1 diabetes mellitus | |
| Zinzani et al. | Hairy cell leukemia: allogeneic transplantation could be an optimal option in selected patients | |
| Jung et al. | Current use of total body irradiation in haploidentical allogeneic hematopoietic stem cell transplantation | |
| Jiang et al. | CD4+ CD25+ regulatory T cells are not required for mesenchymal stem cell function in fully MHC-mismatched mouse cardiac transplantation | |
| Matar et al. | Cellular immunotherapies in preclinical large animal models of transplantation | |
| Fu et al. | Successful transplantation of kidney allografts in sensitized rats after syngeneic hematopoietic stem cell transplantation and fludarabine | |
| Carnevale-Schianca et al. | Allogeneic hemopoietic stem cell transplantation in solid tumors | |
| Strober | Path to clinical transplantation tolerance and prevention of graft-versus-host disease | |
| Ramos et al. | Improved conditioning for hematopoietic chimerism induces islet tolerance to cure diabetes | |
| Lee et al. | Successful salvage unrelated umbilical cord blood transplantation with two units after engraftment failure with single unit in severe aplastic anemia | |
| Beauchemin et al. | 197: Mutated Hoxb4 results in increased intracellular stability affecting both long and short term hematopoietic reconstitution | |
| Wong et al. | Targeted total marrow irradiation using 3D image guided tomographic intensity modulated radiation therapy: An alternative to standard TBI | |
| Bayraktar et al. | Innovative Approaches to Increase the Success of the Haploidentical SCT |